Streetbeat News

Regulatory

HOOK

HOOKIPA Pharma's shares surged following FDA clearance for its Investigational New Drug (IND) application for HB-700, a promising development for the company.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 11:51 am

ARKB

BITB

GBTC

IBIT

Bitcoin spot ETFs experienced a net inflow of $31.6M, led by BlackRock's iShares Bitcoin Trust (IBIT) and followed by Ark's ARKB and Bitwise's BITB, while Grayscale's GBTC saw a notable outflow. Hong Kong is preparing to launch its own Bitcoin and Ether ETFs, aiming to become a regulated hub for the digital asset industry. These developments indicate a growing integration of cryptocurrencies into mainstream finance.

Portfolio Pulse from Murtuza Merchant

April 24, 2024 | 11:50 am

BNBUSD

Changpeng Zhao, founder and former CEO of Binance, faces a potential 3-year prison sentence as the DOJ seeks a harsher punishment than the 18-month plea agreement, citing national security concerns due to Binance's facilitation of illicit transactions. Zhao's defense argues for probation, highlighting his lack of specific knowledge of illegal activities and the relative scale of sanctions violations. Zhao apologizes for his oversight in compliance controls at Binance.

Portfolio Pulse from Murtuza Merchant

April 24, 2024 | 11:49 am

CVAC

GSK

CureVac and GSK have decided to terminate their pandemic preparedness agreement with the German Federal Ministry of Health, initially established in April 2022. This decision was made after consultations with the ministry.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 11:18 am

ETHUSD

Standard Chartered has revised its timeline for US approval of Ether ETFs, citing multiple challenges but remains optimistic about the future of digital assets. Despite setbacks, the bank maintains bullish end-of-year price targets for Bitcoin and Ether. The report highlights significant market adjustments, including the largest daily liquidation of leveraged long positions in the Bitcoin futures market since October 2023.

Portfolio Pulse from Murtuza Merchant

April 24, 2024 | 11:13 am

HOOK

HOOKIPA Pharma has received FDA clearance for its investigational new drug application for HB-700, a therapeutic vaccine targeting KRAS-mutated cancers. This marks a significant step forward in the development of treatments for cancers with these mutations.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 11:02 am

GSK

The FDA has accepted GSK's supplemental Biologics License Application for Jemperli (dostarlimab) in combination with standard-of-care chemotherapy to expand its treatment to all adult patients with primary advanced or recurrent endometrial cancer. This acceptance could potentially broaden the patient base for Jemperli, enhancing its market potential.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:58 am

ALZN

BEEP

CONN

Insiders at Alzamend Neuro, Mobile Infrastructure, and Conn's have recently made significant stock purchases, signaling potential confidence in their companies' futures. Conn's reported a narrower Q4 loss than expected, Mobile Infrastructure is preparing for its Q1 2024 earnings release, and Alzamend Neuro received FDA approval to proceed with a PTSD study.

Portfolio Pulse from Avi Kapoor

April 24, 2024 | 10:54 am

META

SNAP

Shares of Meta Platforms, Inc. (META) and Snap Inc. (SNAP) are trading higher following the passage of a US Senate bill requiring ByteDance to divest TikTok or face a ban of the app.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:20 am

TSLA

Tesla, Inc. (NASDAQ:TSLA) is in talks with a major automaker to license its Full Self-Driving (FSD) software, aiming for true autonomous driving. CEO Elon Musk is optimistic about achieving autonomy, stating Tesla will solve it even in his hypothetical absence. Integration with competitor vehicles is expected to be straightforward but will take time, with a potential deal anticipated this year and integration in about three years. Musk's stance on FSD has evolved, now suggesting that future car purchases will depend on FSD capability. Regulatory approval remains a hurdle, but advancements by other autonomous car companies, like Alphabet Inc's Waymo, are paving the way.

Portfolio Pulse from Anan Ashraf

April 24, 2024 | 9:11 am